Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Asia Pacific Prostate Cancer Conference /
Debate: Will chemotherapy continue to be standard treatment for symptomatic mCRPC in the era of novel agents? (against)

1st - 2nd Mar 2014

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 12.05.14
Views: 2020

Dr Kurt Miller - Benjamin Franklin Medical Center, Berlin, Germany

Dr Kurt Miller from Berlin, Germany, argues against chemotherapy remaining as the standard treatment for symptomatic mCRPC in the era of novel agents.

He shows the strong evidence supporting agents in the pre-chemotherapy space, such as abiraterone and enzalutamide.

He also shows the evidence supporting sipuleucel-T and alpharadin. Dr Miller notes that chemotherapy will still have a role in mCRPC, but probably second-, third- or fourth-line.

 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation